Nicole Schreiber-Agus

Title: The Innovative Contributions of Nicole Schreiber-Agus in Oncogenic Research

Introduction: Nicole Schreiber-Agus is a prominent inventor based in New York, NY, who has made significant strides in the field of cancer research. With two patents to her name, she is recognized for her innovative approaches to suppressing oncogenic activity in tumor cells. Her work is crucial for advancing therapeutic options in oncology, particularly concerning the Myc family oncoproteins.

Latest Patents: Among her groundbreaking inventions, Nicole's latest patents include the invention of the Rep-max protein, which possesses anti-oncogenic activity. This invention introduces a rep-max fusion gene that encodes a protein capable of suppressing the oncogenic activity of Myc family oncoproteins. The patent also covers a vector containing nucleic acid that encodes this protein, along with a vector designed to express the Rep-max protein and a recombinant viral vector that facilitates the introduction of the nucleic acid into target cells. Furthermore, her invention includes methods for inhibiting the growth of tumors in subjects by targeting these oncogenic activities.

Career Highlights: Nicole Schreiber-Agus is affiliated with the Albert Einstein College of Medicine, where she conducts her research and develops her inventions. Her work is esteemed in the academic community and contributes significantly to the understanding of oncogenic mechanisms and the development of potential therapeutic interventions.

Collaborations: One of her notable collaborations includes working with Ronald A. DePinho, a distinguished figure in cancer biology. Their partnership enhances the research effort toward finding innovative solutions for cancer treatment, leveraging their expertise and shared vision.

Conclusion: Nicole Schreiber-Agus exemplifies the spirit of innovation and dedication within the field of cancer research. Her contributions, particularly through her patents involving the Rep-max protein, hold promise for advancing medical therapies and improving patient outcomes in oncology. As a member of the research community at the Albert Einstein College of Medicine, she continues to push the boundaries of scientific understanding and technological application in the fight against cancer.